Cellectis Advances CAR T-Cell Therapy with New Engineering Strategy

Cellectis, a biotechnology company specializing in gene-edited cell therapies, has introduced a groundbreaking approach to improving CAR T-cell treatment for solid tumors. At the AACR-IO 2025 conference in Los Angeles, Dr. Shipra Das presented findings on how the company’s innovative engineering strategy uses a modified interleukin-2 (IL-2) variant to enhance CAR T-cell expansion while avoiding toxicity. This breakthrough could mark a significant step forward in making CAR T-cell therapies more effective for patients battling solid cancers.

By leveraging its TALEN® gene-editing platform, Cellectis has developed "Smart CAR T cells" that activate IL-2 only within the tumor microenvironment, preventing harmful systemic side effects. This localized activation helps boost immune response where it is needed most, improving treatment outcomes while maintaining patient safety. With this advancement, Cellectis aims to reshape the future of immunotherapy, offering new hope for those with hard-to-treat cancers.